Scarica l'app Stockscreener
187.06
1.17%
-2.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$189.28
Aprire:
$189.28
Volume 24 ore:
696.65K
Relative Volume:
0.56
Capitalizzazione di mercato:
$27.62B
Reddito:
$9.60B
Utile/perdita netta:
$1.37B
Rapporto P/E:
20.07
EPS:
9.3182
Flusso di cassa netto:
$2.32B
1 W Prestazione:
+1.45%
1M Prestazione:
+1.78%
6M Prestazione:
+21.25%
1 anno Prestazione:
+54.68%
Intervallo 1D:
$186.14
$190.57
Intervallo di 1 settimana:
$179.15
$195.98
Portata 52W:
$115.25
$202.41
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
187.06 | 27.62B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Aggiornamento | UBS | Neutral → Buy |
| 2026-04-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-09 | Reiterato | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Downgrade | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Aggiornamento | Stifel | Hold → Buy |
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Artemis Investment Management LLP Buys Shares of 226,845 Biogen Inc. $BIIB - MarketBeat
Freedom Broker upgrades Biogen stock rating on Apellis acquisition By Investing.com - Investing.com Canada
Citigroup Adjusts Biogen Price Target to $200 From $190 - marketscreener.com
H.C. Wainwright reiterates Biogen stock rating on tau therapy trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Goldman Sachs Adjusts Biogen Price Target to $250 From $238 - marketscreener.com
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings - Benzinga
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim raises Biogen stock price target to $260 on strong Q1 results - Investing.com
Biogen Inc. Stock (US09062X1037): Analyst Rating Changes and Q1 2026 Earnings Preview - AD HOC NEWS
Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative - simplywall.st
Is Biogen (BIIB) 2.7% Undervalued After Q1 2026? Non-GAAP EPS $3 - GuruFocus
A Look at Biogen Inc (BIIB) After 6.0% Gain -- GF Value $199.82 vs Price $194.38 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard Capital Management (NASDAQ: BIIB) reports 10.99M Biogen shares ownership - Stock Titan
Biogen beats estimates as Alzheimer’s drug gains momentum - The Boston Globe
Biogen Inc. (BIIB.US) 1Q Earnings and Revenue Beat Forecasts - AASTOCKS.com
BofA raises Biogen stock price target on solid quarterly results - Investing.com
BofA raises Biogen stock price target on solid quarterly results By Investing.com - Investing.com Canada
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Biogen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen Q1 Earnings Call Highlights - Yahoo Finance
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs - Yahoo Finance
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge - TechStock²
Earnings call transcript: Biogen Q1 2026 beats expectations with strong EPS and revenue growth - Investing.com
Biogen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus
Biogen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BIIB) 2026-04-29 - Seeking Alpha
Biogen (BIIB) Projects Revenue Decline and Adjusts EPS Forecast for 2026 - GuruFocus
Biogen cuts annual profit forecast on acquisition-related charges - marketscreener.com
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Biogen Q1 Non-GAAP Earnings, Revenue Rise; Cuts 2026 Earnings Outlook - marketscreener.com
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Biogen posts Q1 beat, trims earnings outlook (BIIB:NASDAQ) - Seeking Alpha
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales - Yahoo Finance
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Biogen : BIIB Q1 26 Earnings Presentation Final - marketscreener.com
Biogen : Q1 2026 Earnings Press Release Final - marketscreener.com
Biogen posts Q1 revenue of $2.5B, surpasses estimates - Breakingthenews.net
Biogen Beats Estimates as Alzheimer’s Drug Gains Momentum - Bloomberg.com
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Biogen Q1 2026 earnings preview - MSN
Eyes on Asia: Takesa, Daiichi Sankyo, Biogen - BioXconomy
Is Biogen (BIIB) Still Attractive After Recent Share Price Rebound And DCF Upside Estimate - simplywall.st
Truist reiterates Hold on Biogen stock ahead of tau therapy data - Investing.com Australia
Biogen is entitled to damages in Tecfidera case rules Regional Court Hamburg - JUVE Patent
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biogen Inc Azioni (BIIB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Viehbacher Christopher | President and CEO |
Feb 06 '26 |
Option Exercise |
0.00 |
24,461 |
0 |
36,548 |
| Singhal Priya | Head of Development |
Feb 06 '26 |
Option Exercise |
0.00 |
6,900 |
0 |
12,115 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 06 '26 |
Option Exercise |
0.00 |
8,725 |
0 |
21,016 |
| Kramer Robin | Chief Financial Officer |
Feb 06 '26 |
Option Exercise |
0.00 |
5,003 |
0 |
12,535 |
| Keeney Adam | Head of Corporate Development |
Feb 06 '26 |
Option Exercise |
0.00 |
5,080 |
0 |
6,875 |
| Izzar Rachid | Head of Global Product Strat. |
Feb 06 '26 |
Option Exercise |
0.00 |
6,889 |
0 |
11,786 |
| Grogan Jane | Head of Research |
Feb 06 '26 |
Option Exercise |
0.00 |
3,258 |
0 |
4,642 |
| Gregory Ginger | EVP, Human Resources |
Feb 06 '26 |
Option Exercise |
0.00 |
7,183 |
0 |
23,491 |
1.39%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):